Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Victoria Seewaldt, MD
City of Hope Medical Center
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
27 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope Comprehensive Cancer Center
Duarte, California, United States
- Los Angeles County-Usc Medical Center
Los Angeles, California, United States
- Usc / Norris Comprehensive Cancer Center
Los Angeles, California, United States
- City of Hope South Pasadena
South Pasadena, California, United States
- the Community Hospital
Munster, Indiana, United States
- University of Kansas Cancer Center
Kansas City, Kansas, United States
- Cotton O'Neil Cancer Center / Stormont Vail Health
Topeka, Kansas, United States
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
- Roswell Park Cancer Institute
Buffalo, New York, United States
- Mount Sinai Hospital
New York, New York, United States
- Nyp/columbia University Medical Center/herbert Irving Comprehensive Cancer Center
New York, New York, United States
- Duke University Medical Center
Durham, North Carolina, United States
- the Christ Hospital
Cincinnati, Ohio, United States
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
- University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
- Prisma Health Cancer Institute - Spartanburg
Boiling Springs, South Carolina, United States
- Prisma Health Cancer Institute - Easley
Easley, South Carolina, United States
- Greenville Health System Cancer Institute-Andrews
Greenville, South Carolina, United States
- Prisma Health Cancer Institute - Butternut
Greenville, South Carolina, United States
- Prisma Health Cancer Institute - Eastside
Greenville, South Carolina, United States
- Prisma Health Cancer Institute - Faris
Greenville, South Carolina, United States
- Prisma Health Greenville Memorial Hospital
Greenville, South Carolina, United States
- Prisma Health Cancer Institute - Greer
Greer, South Carolina, United States
- Prisma Health Cancer Institute - Seneca
Seneca, South Carolina, United States
- M D Anderson Cancer Center
Houston, Texas, United States
- Doctor'S Hospital of Laredo
Laredo, Texas, United States
- University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 23 Nov 2015
- Primary completion
- 10 Nov 2023
- Completion
- 30 Nov 2026
- Last update posted
- 28 Apr 2026
- Registered enrollment
- 86
- Registry id
- NCT01905046
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.